Showing results (21-30 of 224) with videos related to

Sort By:
Pageof 23
Molecular & Cellular Oncology|February 7, 2018
Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitorsMarta Kovatcheva, Mary E Klein, William D Tap, et al.
The Journal of Biological Chemistry|October 26, 2011
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cellsBenjamin A Nacev, Paola Grassi, Anne Dell, et al.
Pediatric Research|May 2, 2012
Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilitiesJennifer L Anderson, Christopher T Denny, William D Tap, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2023
Stereotactic body radiation therapy for sarcoma pulmonary metastasesEmily S Lebow, Stephanie M Lobaugh, Zhigang Zhang, et al.
Cancer Cell|May 8, 2018
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once ThoughtMary E Klein, Marta Kovatcheva, Lara E Davis, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Establishing a Mutually Respectful Environment in the Workplace: A Toolbox for Performance ExcellenceNarjust Duma, Shail Maingi, William D Tap, et al.
Journal of Medicinal Chemistry|September 23, 2011
Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signalingWei Shi, Benjamin A Nacev, Blake T Aftab, et al.
Nature Communications|June 17, 2024
Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiationBenjamin A Nacev, Yakshi Dabas, Matthew R Paul, et al.
Cellular Signalling|February 28, 2017
Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activationAlbert J van Hell, Adriana Haimovitz-Friedman, Zvi Fuks, et al.
Pageof 23